Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Yum! Brands, Inc. — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Yum! Brands, Inc. trades at $146.68 (market cap $40.13B). The key difference: Yum! Brands, Inc. is far larger — about 8.2× Travere Therapeutics Inc. Common Stock's market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Yum! Brands, Inc. for 133 Days on average.
| TVTX | YUM | |
|---|---|---|
Market Cap | $4.88B | $40.13B |
Volume | 1,668,577 | 2,329,777 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $168.16 |
52-Week Low | $26.79 | $135.77 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $5.01B | $51.73B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
YUM Brands trades at $146.69, showing minimal daily movement (-0.04%). The stock maintains a bullish technical outlook with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, YUM demonstrates solid revenue growth from $8.21B in 2025 to projected $8.7B in 2026, with net income margins improving to 25.4%. Recent strategic moves include the Pizza Hut divestiture and KFC's Open House concept launch, positioning the company for focused growth in its core brands.
YUM presents a compelling opportunity with analyst consensus target of $170.44 (16% upside), supported by consistent earnings beats and dividend growth. However, high debt levels ($11.25B long-term) and competitive pressures in the QSR space present notable risks. The company's streamlined portfolio and operational efficiency improvements provide catalysts for continued shareholder value creation amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
